Similar to βI, in lung adenocarcinoma, breast cancer, and breast cancer cell lines, an increased level of βII was associated with resistance to MTA [191,196,201], while in LASCCHN, it was associated with poor survival after chemotherapy [198]. The gene discussed is CACNA1E; the disease is breast cancer.